CeriBell (NASDAQ:CBLL) Director Sells $54,725.00 in Stock

CeriBell, Inc. (NASDAQ:CBLL) Director Rebecca Robertson sold 2,500 shares of the business’s stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $21.89, for a total transaction of $54,725.00. Following the transaction, the director owned 19,576 shares in the company, valued at $428,518.64. This represents a 11.32% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

CeriBell Stock Up 4.4%

CBLL traded up $0.92 on Tuesday, hitting $21.73. The company had a trading volume of 308,750 shares, compared to its average volume of 515,383. The company has a debt-to-equity ratio of 0.12, a current ratio of 12.65 and a quick ratio of 12.25. CeriBell, Inc. has a 52-week low of $10.01 and a 52-week high of $26.04. The stock has a fifty day simple moving average of $17.15 and a 200-day simple moving average of $14.94. The firm has a market capitalization of $806.18 million, a P/E ratio of -14.39 and a beta of 1.02.

CeriBell (NASDAQ:CBLL) last posted its earnings results on Tuesday, November 4th. The company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.06. The firm had revenue of $22.59 million for the quarter, compared to the consensus estimate of $21.78 million. CeriBell had a negative return on equity of 29.63% and a negative net margin of 63.35%. As a group, equities analysts expect that CeriBell, Inc. will post -2.46 EPS for the current fiscal year.

Institutional Trading of CeriBell

A number of institutional investors and hedge funds have recently bought and sold shares of CBLL. Ameritas Investment Partners Inc. raised its holdings in CeriBell by 97.5% in the second quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company’s stock worth $48,000 after buying an additional 1,256 shares during the last quarter. Tower Research Capital LLC TRC increased its position in shares of CeriBell by 353.8% during the second quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock valued at $43,000 after acquiring an additional 1,801 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in CeriBell in the 3rd quarter worth approximately $33,000. Rhumbline Advisers raised its holdings in CeriBell by 26.5% in the 1st quarter. Rhumbline Advisers now owns 15,629 shares of the company’s stock worth $300,000 after acquiring an additional 3,276 shares during the last quarter. Finally, Sei Investments Co. lifted its position in CeriBell by 7.1% in the 3rd quarter. Sei Investments Co. now owns 50,454 shares of the company’s stock valued at $580,000 after acquiring an additional 3,365 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on CBLL shares. Weiss Ratings restated a “sell (e+)” rating on shares of CeriBell in a report on Wednesday, October 8th. JPMorgan Chase & Co. decreased their price target on shares of CeriBell from $21.00 to $17.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. Raymond James Financial initiated coverage on shares of CeriBell in a research note on Tuesday, October 21st. They set a “strong-buy” rating and a $19.00 price objective on the stock. Canaccord Genuity Group upped their price objective on shares of CeriBell from $29.00 to $30.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th. Finally, TD Cowen lowered their target price on shares of CeriBell from $36.00 to $20.00 and set a “buy” rating for the company in a report on Wednesday, November 5th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, CeriBell has a consensus rating of “Moderate Buy” and a consensus price target of $24.67.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.